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ABSTRACT 
 
Genomic instability, a hallmark of cancer, is generally thought to occur in the mid to late 
stages of tumorigenesis, following the acquisition of permissive molecular aberrations such 
as TP53 mutation or whole genome doubling. Tumours with somatic POLE exonuclease 
domain mutations are notable for their extreme genomic instability (their mutation burden is 
among the highest in human cancer), distinct mutational signature, lymphocytic infiltrate and 
excellent prognosis. To what extent these characteristics are determined by the timing of 
POLE mutations in oncogenesis is unknown. Here, we have shown that pathogenic POLE 
mutations are detectable in non-malignant precursors of endometrial and colorectal cancer. 
Using genome and exome sequencing, we found that multiple driver mutations in POLE-
mutant cancers display the characteristic POLE mutational signature, including those in genes 
conventionally regarded as initiators of tumorigenesis. In POLE-mutant cancers, the 
proportion of monoclonal predicted neoantigens was similar to other cancers, but the absolute 
number was much greater. We also found that the prominent CD8+T cell infiltrate present in 
POLE-mutant cancers was evident in their precursor lesions. Collectively, these data indicate 
that somatic POLE mutations are an early, quite possibly initiating, event in the endometrial 
and colorectal cancers in which they occur. The resulting early onset of genomic instability 
may account for the striking immune response and excellent prognosis of these tumours, as 
well as their early presentation. 
 
Keywords 
POLE, polymerase proofreading, mutation, endometrial cancer, colorectal cancer, precursor 
lesion 
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INTRODUCTION 
 
Next generation sequencing (NGS) technologies have, hugely, advanced our understanding of 
the mechanisms of tumorigenesis. The ability to analyse the entire genome or exome at depth 
in large numbers of tumours has substantially increased the list of driver genes – that is those 
which, when mutated, promote tumour growth. It has also revealed that such driver mutations 
are not always present in the dominant tumour clone [1,2]. This is clinically relevant, because 
targeting subclonal drivers is likely to kill only a subpopulation of tumour cells, while 
successful targeting of clonal variants may lead to tumour eradication. Thus, differentiating 
early, clonal mutations from late, subclonal ones may not only increase our understanding of 
the mechanisms of oncogenesis, but also inform the clinical management of patients [2].  
 
Fundamentally, all mutations are caused in part by a failure to recognise or repair defects in 
DNA sequence or chromosome structure. In many cancers, this is a consequence of specific 
defects in the cellular processes responsible for maintaining genomic integrity [3]. One 
recently described example is the genomic instability caused by missense mutations in the 
exonuclease (proofreading) domains of the major replicative DNA polymerases POLE and 
POLD1 [4]. Polymerase proofreading recognises and corrects mispaired bases incorporated 
during DNA replication; its perturbation as a result of these mutations is associated with an 
exceptional number of SNVs (though not indels), and a distinct mutational signature typified 
by C:G→A:T transversions where the mutated cytosine is in the context TCT, and C:G→T:A 
transitions where the mutated cytosine is in the context TCG [4-6]. POLE and POLD1 
exonuclease domain mutations may occur in the germline, where they cause polymerase 
proofreading-associated polyposis (PPAP) – a condition characterised by intestinal polyposis 
and tumours of the colorectum and uterus, among other organs [7]. Somatic POLE 
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exonuclease domain mutations (hereafter simply referred to as POLE mutations) occur in 
sporadic tumours of the endometrium (7-15% cases) [8,9], colorectum (1-2%) [10,11], and 
less commonly in other cancers (although for reasons that are unclear, somatic POLD1 
exonuclease domain mutations are very uncommon). POLE-mutant colorectal and 
endometrial cancers have an excellent prognosis [8,11-13], probably owing to a robust anti-
tumour immune response against the multitude of immunogenic neoantigens they are 
predicted to harbour [11,14,15]. Very recent reports also suggest that these tumours may be 
highly responsive to immune checkpoint inhibition [16].  
 
While it is clear that somatic POLE mutation causes a mutator phenotype [17] and acts as a 
cancer driver [4,5], several questions about its contribution to tumorigenesis remain 
unanswered. One of the most important of these relates to the timing of these mutations in 
cancer development. If POLE mutations are late events, their consequences may be restricted 
to a subclone of tumour cells, the targeting of which may fail to alter meaningfully tumour 
behaviour. In contrast, if POLE mutations occur early, they could rapidly cause a large 
number of clonal alterations that may alter prognosis or response to therapy. This is 
particularly pertinent in the light of recent data suggesting that long-term benefit from 
immune checkpoint inhibition is limited to patients whose cancers harbour neoantigens in the 
dominant tumour clone [18]. In contrast to germline mutations in DNA repair pathways in 
rare inherited syndromes (such as the mismatch repair gene variants that cause Lynch 
syndrome), the acquisition of genomic instability in sporadic cancers has largely been 
believed to be a mid- to late-stage event during carcinogenesis [19]. For example, in sporadic 
colorectal cancer – a tumour type in which the molecular progression of pre-cancers 
(adenomas) to invasive carcinomas has been well characterised – mismatch repair deficiency 
(MMR-D) or chromosomal instability (CIN) occur after initiating (epi)mutations in APC, 
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BRAF or KRAS, or other events such as whole genome doubling or loss of chromosome 18q 
[19-24]. Thus, in addition to its clinical relevance, the demonstration that the POLE mutator 
phenotype operates from the first stages of tumour initiation would also reveal a novel 
pathway of sporadic tumorigenesis. A recent case report of a pathogenic POLE mutation in a 
endometrial cancer and its precursor [25] suggests that these mutations may occur early in 
tumour development, but the single case precludes generalization of this result.  
 
In this study, we comprehensively examined the timing of pathogenic somatic POLE 
exonuclease domain mutations in sporadic endometrial and colorectal cancers using tumour 
whole genome sequencing (WGS), public sequencing data from The Cancer Genome Atlas 
(TCGA) [8,10], and targeted sequencing of additional cohorts of cancers and pre-cancers.  
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Materials and methods 
Ethical approval 
 
Patient consent for research on tumour tissue was obtained at the recruiting centres under 
local ethical approval. Molecular analysis of anonymised tissue was performed under Oxford 
Research Ethics Committee A approval (05/Q1605/66). 
 
Patients and tumour samples 
 
Details of the cohorts and cases analysed in this study are shown in supplementary material, 
Tables S1 and S2.  Fifty one formalin-fixed paraffin-embedded (FFPE) endometrial cancers 
carrying known pathogenic somatic POLE exonuclease domain mutations identified in our 
previous studies [12,14,26] were reviewed for the presence of a concomitant and spatially 
discrete area of endometrial intraepithelial neoplasia (EIN) by examination of haematoxylin 
and eosin (H&E) stained slides by two expert gynaecological pathologists (VS & TB). An 
additional 389 FFPE colorectal polyps (tubular adenomas, tubulovillous adenomas and 
serrated adenomas – hereafter referred to as adenomas), for which POLE screening had not 
previously been performed, were identified from 261 participants in the CORGI study, which 
recruited patients with a family history of colorectal cancer and a personal history of a 
colorectal polyp or colorectal malignancy in the absence of a known tumour predisposition 
syndrome. Six fresh frozen tumours with pathogenic somatic POLE mutations (five 
endometrial, one colorectal) were identified from a Leuven endometrial cancer cohort used in 
our previous study [12], a prospective clinical sequencing programme (HICF2) at the 
University of Oxford, or the University of Birmingham tissue bank. TCGA colorectal 
(COADREAD) [10] and endometrial (uterine corpus endometrial carcinoma – UCEC) [8] 
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cancer data were downloaded from the Genomic Data Commons (GDC) Data Portal 
(https://portal.gdc.cancer.gov; June 2017). An additional series of 78 FFPE endometrial 
cancers including 32 cases with pathogenic somatic POLE mutations were identified from the 
LUMC archives (2001-2015) [14]. Further details of the cohorts used in this study are 
provided in supplementary material, Table S1. Molecular analyses were performed on a 
single tumour or precursor lesion region in each case. 
 
 
DNA extraction  
 
After review to confirm adequate tumour cellularity, DNA was extracted from fresh frozen or 
microdissected FFPE tumours and precursors using standard methods (Roche FFPE-T DNA 
kit (F. Hoffman La Roche AG, Basel, Switzerland), Machery Nagel Nucleospin DNA FFPE 
XS (Machery Nagel, Duren, Germany)/ FFPE DNA kit or Qiagen Blood and Tissue kit 
(Qiagen, Hilden, Germany) and resuspended in buffer or water.  
 
 
DNA sequencing 
 
Full details of the sample preparation and the sequencing methods utilized in this study are 
provided in supplementary material, Supplementary materials and methods. In brief, 
endometrial epithelial neoplasias (EIN) and paired carcinomas were sequenced for mutations 
in 30 cancer genes using molecular inversion probe capture, and a custom version of the 72 
gene Ion AmpliSeq Cancer Hotspot panel v2 (including 80 genes; ThermoFisher, MA, USA) 
(supplementary material, Tables S3,4). Whole genome sequencing (WGS) of fresh frozen 
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tumours was performed by Illumina HiSeq (Illumina, San Diego, CA, USA), and aligned to 
the reference genome by BWA mem or Isaac [27]. FFPE endometrial cancers from the 
LUMC series were analysed using the Lifetech/ThermoFisher Ion AmpliSeq Comprehensive 
Cancer Panel comprising 409 cancer genes 
(http://www.lifetechnologies.com/order/catalog/product/4477685). Mutation calling was 
performed by LoFreq [28] (EINs), Mutect, Mutect2 [29] or Strelka [30] (WGS, TCGA 
cases), or Ion Torrent variantCaller (EINs, LUMC FFPE tumours). Copy number profiles 
were derived using Sequenza [31]. Variant annotation was done using Annovar [32] or 
Variant Effect Predictor [33].  
 
Definition of driver genes 
 
Driver genes were defined using the IntOGen driver gene repository 
(https://www.intogen.org/search) and included both PanCancer (Pooled_driver) and tumour 
type-specific (perProject_driver) variants (supplementary material, Tables S5, S6) [34]. High 
confidence driver mutations (defined as either truncating mutations in genes likely to be 
tumour suppressors or recurrent missense mutations in any endometrial or colorectal cancer-
specific or pan-cancer gene from the IntOGen set) were determined for a subset of driver 
genes by manual curation, blinded to tumour molecular characteristics. 
 
Clonality of POLE mutations 
 
Most (36 of 38) endometrial and colorectal cancers with pathogenic POLE mutations were 
disomic at the POLE locus (chr12q24) and were informative for clonality analysis. Of these, 
20 of 22 endometrial cancers, and 12 or 14 colorectal cancers had available copy number 
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annotation. As all 32 of these showed near-diploid genomes (>80% of the genome), we 
assumed diploid genomes for the four remaining cases.  
 
Mutations were filtered to include only autosomal variants in diploid regions of the genome, 
called with depth of at least 20x. Mutation allele frequency distributions were generated using 
the R ‘histogram’ function, and tumour cellularity inferred as twice the mid-point of the allele 
frequency bin with highest mutation density, excluding bins with a lower bound below allele 
frequency 0.1. These values were then subjected to manual curation. The hypothesis that the 
mutation was present in every tumour cell was tested by a one-sided binomial test, based on 
the numbers of reference and variant reads at the POLE mutation site and the inferred tumour 
cellularity. Specifically, for a mutation with coverage R, in a tumour with tumour cell 
fraction C, the number of variant reads was modelled as a random variable X, with 
distribution: 
 
X ~ Binom(R, C / 2). 
 
In each case we calculated the probability, p, of finding the observed number of variant reads, 
v, or fewer, P(X<=v). Mutations were considered subclonal for p<=0.05. 
 
Mutational signatures 
 
Previously reported mutational signatures were obtained from 
http://cancer.sanger.ac.uk/cosmic/signatures/ on 1 June 2017. The complement of mutational 
processes active in the life-history of each tumour sample was inferred by classification of 
mutations into 96 categories following Alexandrov [6], and the use of non-negative least 
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squares regression, implemented in the R package ‘nnls’. For this analysis, only mutational 
signatures previously reported as active in that cancer type (endometrial signatures 1, 2, 5, 6, 
10, 13, 14 and 26; colorectal signatures 1, 5, 6, and 10) were used for the regression. For 
cases analysed by whole exome sequencing, mutational signatures were re-scaled to exomic 
trinucleotide frequencies. A mutational process was deemed to have been active in the life-
history of a tumour if the associated mutational signature had a coefficient of at least 2 per 
cent of the total coefficients in the best-fitting model. Mutations likely to be due to POLE 
exonuclease domain mutation (POLE) were identified by considering mutational signatures 
as multinomial probability distributions caused by specific mutational processes. The 
probability of each mutation under all mutational processes active in that tumour was 
calculated, and mutations were assigned to the “POLE” mutational process in cases where the 
probability under that process was at least twice the probability under any other process.  
 
 
POLE consensus mutational signature scores in driver genes 
 
Tumour mutations were obtained from calling based on tumour/normal .bam files (POLE 
mutant cases) or TCGA MAF files (MMR-P, MMR-D cases), and classified into 96 
categories following Alexandrov [6]. For each tumour, the distribution of mutations across 
the 96 types was calculated, and re-scaled to equal trinucleotide frequencies based on 
sequencing type, thus obtaining an individual tumour mutational signature. Tumours were 
then categorised into three groups according to POLE mutation and mismatch repair status 
(i.e. POLE-mutant, MMR-P and MMR-D), and a consensus mutational signature was 
calculated for each group as the average of the individual-tumour signatures among samples 
in the group, weighted by the number of mutations in each sample. The probability of all non-
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silent mutations (‘nonsynonymous SNV’, or ‘stopgain’) in driver genes (as defined above) 
under each of the three consensus mutational signatures was then calculated, and the ratio of 
the probability of each mutation under the POLE consensus mutational signature compared to 
that under each of the other two consensus mutational signatures was obtained. For each 
individual gene, a ‘POLE score’ was then calculated as the base two logarithm of the 
minimum value of these ratios across all the non-silent mutations within that gene. 
 
Immunohistochemistry 
 
Immunohistochemistry (IHC) for CD8 was performed as reported previously [14]. The 
number of CD8+ cells was quantified for the epithelial and stromal regions of the EIN. For the 
final CD8 count per case, the mean of these regions in ten high-power fields (HPF; 625 μm x 
425 μm) was calculated. A similar method was used to quantify CD8 density in colorectal 
adenomas, although the small lesion size meant that estimates were obtained from the mean 
of two or three HPFs. 
 
 
Clonal neoantigen prediction 
 
We estimated the number of clonal neoantigens using a modification of our previously-
reported algorithm [11], modified to predict peptide binding against patient-specific HLA 
molecules (determined from WGS or WES data using OptiType [35]). Neoantigens were 
defined as mutations predicted to specify peptides that bound patient HLA molecules with 
affinity <500 nM. Copy number information was obtained from the GDC data portal, as 
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described above. Clonality was determined as described above. Neoantigens were considered 
clonal if the binomial test P-value was over 0.05. 
 
 
Statistical analysis 
 
Analyses were performed using R (CRAN network) or Prism (GraphPad Software, La Jolla, 
CA, USA). Statistical comparison between groups was made using the non-parametric Mann-
Whitney U test. All P values were two sided, unless otherwise specified. Statistical 
significance was accepted at P<0.05.  
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RESULTS 
 
Somatic POLE exonuclease domain mutations are detectable in sporadic endometrial and 
colorectal pre-cancers  
 
As somatic POLE exonuclease domain mutations have been best characterised in endometrial 
and colorectal cancers, we first examined whether these mutations were present in precursors 
of these malignancies. Expert histopathological review of 51 POLE-mutant endometrial 
cancers revealed four with a concomitant and spatially discrete area of endometrial 
intraepithelial neoplasia (EIN), the precursor of endometrioid carcinoma (supplementary 
material, Table S2). Microdissection and targeted sequencing of these lesions by a 30-gene 
molecular inversion probe capture NGS panel (supplementary material, Table S3), a custom 
80 gene Ion Ampliseq Cancer Hotspot panel (supplementary material, Table S4) and Sanger 
sequencing revealed that in all cases, the POLE mutation present in the carcinoma was also 
detectable in the paired precursor (Figure 1A,B, supplementary material, Table S7). While 
some other driver mutations were also shared between the precursors and paired cancers 
(median 4 shared mutations per pair, relative to a median of 7 mutations per EIN and median 
of 10 mutations per carcinoma), the progression from EIN to malignancy was associated with 
both the loss (median 3 mutations lost in carcinomas compared to paired EINs) and, more 
frequently, gain (median 6 mutations gained in carcinomas compared to paired EINs) of 
driver mutations (Figure 1A,B, supplementary material, Table S7). Notably, many of the 
driver mutations gained were replacements of a glutamic acid or arginine codon with a 
nonsense codon (E→* or R→ *), consistent with the characteristic mutational bias associated 
with POLE mutation (C:G→A:T transversions where the mutated cytosine is in the context 
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TCT, and C:G→T:A transitions where the mutated cytosine is in the context TCG) [4-6] 
(Figure 1B, supplementary material, Table S7).  
 
We were unable to perform a corresponding analysis of colorectal tumours, because residual 
precursor is uncommon in colorectal carcinomas. However, screening of 389 colorectal 
adenomas from 261 patients revealed three (0.8% adenomas, 1.1% patients) with somatic 
POLE mutations (Figure 1C), a frequency concordant with that found in colorectal cancers 
[11]. Unfortunately, the limited amount of DNA available from these lesions precluded 
analysis of other driver mutations.   
 
 
Mutational landscape and driver gene alterations suggest that somatic POLE mutation is an 
early event in sporadic endometrial and colorectal cancers 
 
To further investigate the timing and consequences of POLE mutations in tumour 
development, we performed WGS on six cancers (five endometrial, one colorectal), all of 
which harboured the most common pathogenic POLE exonuclease domain variant – a proline 
to arginine substitution at codon 286 (POLEP286R) (Figure 2A). Each displayed a substantially 
elevated mutation burden (122–731 mutations/Mb), and characteristic preponderance of 
C:G→A:T substitutions in the context TCT (Figure 2A,B, supplementary material, Table S8, 
Figure S1) [6]. In keeping with their early occurrence, both the POLE mutations themselves, 
and other mutations consistent with the known POLE mutational signature (see Materials and 
methods, Mutational signatures) appeared clonal in all six cases (Figure 2C). This was also 
the case in 17 of 17 endometrial cancers and 12 of 13 colorectal cancers with pathogenic 
POLE exonuclease domain mutations from the TCGA series (supplementary material, 
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Figures S2, S3). This analysis showed that POLE mutations were unlikely to occur as late 
events after the most recent common ancestor in cancer evolution. 
 
We next examined the timing of POLE mutations in carcinogenesis in more detail by analysis 
of driver genes, including some known usually to be mutated early in the pathogenesis of 
endometrial or colorectal cancer. To assess the likelihood that mutations in these genes were 
secondary to an earlier POLE mutation, we developed a metric to score them according to the 
probability that they were caused by the mutational process dominant in POLE-mutant 
cancers (presumably caused by the POLE mutation itself), rather than the mutational 
processes operative in other tumours (see Materials and methods, POLE consensus 
mutational signature score for details). For this analysis, we combined our cohort of POLE-
mutant tumours with POLE-mutant cases from TCGA, using MMR-P and MMR-D TCGA 
cases as comparators. Strikingly, in POLE-mutant tumours, almost all known cancer driver 
genes displayed evidence of the POLE consensus mutational signature, with the notable 
exception of POLE itself (Figures 3,4, supplementary material, Tables S8–S10, Figures S4, 
S5), consistent with the postulate that the POLE signature is a direct effect of the polymerase 
proofreading mutation. In contrast, MMR-P and MMR-D tumours rarely showed evidence of 
the POLE consensus mutational signature (Figures 3,4, supplementary material, Tables S8–
S10). In total, among 206 endometrial and/or colorectal cancer driver genes examined in the 
cases from the combined endometrial and colorectal cancer cohorts, 50% (1,065/2,118) of 
those in POLE mutant samples had a POLE signature score >0, compared to 14% 
(628/4,427) in MMR-D and MMR-P cancers (P<1x10-26). 
 
To minimise the possibility of confounding by non-pathogenic mutations in the complete set 
of driver genes, we repeated these analyses considering only manually curated, high-
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confidence pathogenic mutations, and obtained similar results (P<1x10-26, supplementary 
material, Figures S6, S7). As mutation of the tumour suppressors PTEN and APC are well 
recognised as early, if not initiating, events in the pathogenesis of endometrial and colorectal 
cancers respectively, we specifically examined whether somatic variants in these genes varied 
according to tumour POLE mutation status. Among high-confidence pathogenic PTEN 
mutations in endometrial cancers, the proportion with POLE consensus mutational signature 
scores >0 was substantially and significantly greater among POLE-mutant cases than among 
MMR-P and MMR-D tumours (10 of 14  [71.4%] versus 14 of 82 [17.1%] mutations 
respectively; P=7.8x10-3, Fisher’s Exact Test). Analysis of high-confidence pathogenic APC 
mutations in colorectal cancers revealed similar results (corresponding proportions 9 of 14 
[64.3%] versus 10 of 69 [14.5%] mutations; P=0.012, Fisher’s Exact Test).   
 
Further analysis of these cohorts and of targeted sequencing data from an additional series of 
endometrial cancers from the Leiden University Medical Centre (LUMC), including 32 
POLE-mutant tumours, confirmed the over-representation of E→*, R→* and arginine to 
glutamine substitutions (R→Q) among POLE-mutant cases, concordant with the results from 
the paired endometrial lesions and consistent with the known trinucleotide bias of the POLE 
mutational signature (supplementary material, Figure S8, S9, S10, Tables S7-S11). 
Interestingly, this was evident not only in well characterised drivers such as PTEN in 
endometrial cancer and APC in colorectal cancer as noted above, but also in recurrent, clonal 
driver mutations found rarely in that tumour type. For example, in the combined 
TCGA/LUMC endometrial cancer cohorts, truncating mutations in the tumour suppressors 
APC, NF1 and RB1 were very rare in POLE-wild-type tumours (1.1%, 1.5% and 1.5% 
respectively), but common among POLE-mutant cases (38.8%, 34.7% and 34.7% 
respectively; P<0.001 for each comparison, Fisher’s exact test), where they almost invariably 
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occurred at glutamic acid or arginine codons (supplementary material, Figure S8, S9, S10, 
Tables S9, S11).  
 
Collectively, these data suggested that somatic POLE mutation occurs early in endometrial 
and colorectal cancers, and that its attendant mutator phenotype defines a distinct pathway of 
carcinogenesis from the initial stages of this process.  
  
 
Somatic POLE mutations are associated with a prominent T cell infiltrate in both 
precancerous and cancerous lesions 
 
Somatic POLE exonuclease domain mutations in endometrial and colorectal cancers are 
associated with enhanced tumour immunogenicity and favourable prognosis [11,14,15]. We 
speculated that the early acquisition of somatic POLE mutations would cause a rapid 
acquisition of mutations, some of which would produce neoantigens capable of eliciting an 
anti-tumour immune response. Consistent with this prediction, all POLE-mutant EINs 
displayed a prominent CD8+ infiltrate (Figure 5A), which was significantly greater than that 
in POLE-wild-type EINs (median 59.4 versus 14.8 CD8+ cells per high power field [HPF]; 
P=0.029 Mann Whitney U test), and exceeded that observed in the POLE-wild-type 
endometrial carcinomas, although this difference was not statistically significant (median 
59.4 versus 24.7 CD8+ cells per HPF, P=0.11) (Figure 5B). The increased CD8+ cell density 
in POLE-mutant EINs could not obviously be explained by other factors such as patient age, 
or the stage or grade of the paired carcinoma (supplementary material, Table S2). In contrast, 
the differences in CD8+ density between EINs and paired carcinomas among both POLE-
wild-type and POLE-mutant cases were less marked (median 14.8 versus 24.7; P=0.34, and 
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59.4 versus 116.9; P=0.11 respectively). The single POLE-mutant colorectal adenoma for 
which IHC was possible also demonstrated a dense CD8+ infiltrate (154.9 versus median 34.0 
CD8+ cells per HPF) (Figure 5A,B).  
 
 
Somatic POLE mutations in colorectal cancer are associated with enhanced predicted clonal 
neoantigen burden  
 
Recent data have shown that the presence of predicted neoantigens within the major tumour 
clone correlates with benefit from immune checkpoint inhibitor therapy [18]. As the limited 
amount of FFPE-derived DNA from precursor lesions was inadequate for clonality analysis 
and neoantigen prediction, we examined predicted neoantigen clonality in a subset of TCGA 
colorectal cancers including MMR-P, MMR-D and POLE-mutant subtypes, broadly matched 
for patient age and tumour stage. We used an approach similar to our previous reports 
[11,14], modified to incorporate patient-specific HLA haplotypes obtained using OptiType 
[35] and estimates of tumour clonality derived from analysis of variant allele frequencies 
(See Materials and methods, Clonal neoantigen prediction). Analysis of our combined cohort 
by this pipeline confirmed that POLE-mutant colorectal cancers harboured a substantially 
greater number and density of predicted clonal neoantigens (0.12 per Mb) than tumours 
lacking POLE mutations, including both MMR-P (0.0029 per Mb; P=0.0002, Mann Whitney 
U test) and hypermutated MMR-D cases (0.044 per Mb; P=0.03) (Figure 6, supplementary 
material, Figure S11).   
 
 
DISCUSSION 
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In this study, we have presented multiple lines of evidence to show that pathogenic, somatic 
POLE exonuclease domain mutations are usually early and as far as we can detect initiating 
events in endometrial and colorectal tumorigenesis. We show that the acquisition of POLE 
mutation causes a distinct pattern of mutations in cancer driver genes, substantially increased 
mutation burden and an enhanced immune response, detectable even in precancerous lesions. 
Furthermore, we show that early somatic POLE exonuclease domain mutations are likely to 
cause an enrichment of clonal neoantigens that may explain their good prognosis and 
excellent response to immune checkpoint inhibitors. 
 
APC mutation has traditionally been regarded as the initiating event in sporadic colorectal 
cancers that develop along the canonical pathway [19], while mutation of PTEN is thought to 
play a similar role in sporadic endometrioid endometrial cancers [36]. Our evidence suggests 
that in sporadic colorectal and endometrial cancers with pathogenic somatic POLE mutations, 
the POLE mutation is antecedent to either of these events. The consequent mutator phenotype 
it causes influences the type of mutations in these genes and that of the other earliest driver 
mutations in these cancers, as well as determining their overall mutational landscape [6]. 
Whether any of these POLE-induced driver mutations represent targetable alterations will be 
an important topic for future research. Similarly, while the increased burden of predicted 
clonal neoantigens in POLE-mutant tumours may explain their enhanced immunogenicity, 
further work is required to understand the molecular factors that determine this and its 
therapeutic implications. A further intriguing possibility is that the mutator phenotype and 
mutational bias drives cancers into an evolutionary cul-de-sac of sub-optimal fitness. The 
presence of APC mutations as an alternative to CTNNB1 mutations in some POLE-mutant 
endometrial cancers is an exemplar, and there are likely to be others, such as NF1 and RB1 
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mutations in endometrial cancer and atypical (Q61P, K117N and A146T) KRAS mutations in 
colorectal cancer.  Examination of this hypothesis by comparing the oncogenic effects of 
these uncommon mutations with those caused by more typical variants in model systems 
would be of considerable interest.  
 
Our data add to the expanding body of evidence suggesting that the effects of genomic 
instability in cancer depend upon both its severity and timing. For example, upregulation of 
APOBEC cytosine deaminase enzymes is common in many types of cancers, resulting in an 
increased mutation rate and characteristic mutation spectrum [6]. However, APOBEC 
overexpression often occurs as a late event in advanced tumours and causes a more modest 
mutator phenotype than POLE mutations [2,6]. Speculatively, these features may explain 
why the impact of APOBEC on prognosis appears more variable than that of POLE mutation 
[37,38]. The early acquisition of somatic POLE mutations in sporadic cancers may also help 
to explain their association with young age at diagnosis, given the prediction that the early 
gain of a mutator phenotype will accelerate the process of malignant transformation [39]. 
 
Our study has limitations. The number of precursor lesions informative for detailed analysis 
was limited, in keeping with the relative rarity of POLE mutations in endometrial cancer, and 
the frequency with which precancerous and cancerous lesions occur in the same tumour 
section. Moreover, although the spatial separation of the precancerous and cancerous 
compartments, and the discordance in molecular alterations between the two components in 
each case suggests otherwise, we cannot exclude the possibility that the apparent precursor 
lesion is in fact adenocarcinoma colonizing endometrial glands. It will therefore be important 
to validate our results in additional cohorts, although we note that a very recent study has 
documented a pathogenic POLE mutation in an endometrial cancer precursor [25]. 
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Furthermore, all our results are based on the analysis of a single sample of each cancer, 
meaning that the effects of intratumour heterogeneity on the pattern of driver mutations and 
clonal neoantigens in POLE-mutant tumours requires further definition. However, the 
absence of multi-region sequencing is unlikely to have confounded the principal conclusions 
of our study regarding the timing of these pathogenic mutations in cancers.  
 
In summary, we show that pathogenic, somatic POLE exonuclease domain mutations are 
early, quite possibly initiating, events in sporadic cancers, and strongly shape subsequent 
tumour evolution. Our observation provides further insights into the distinct biology of these 
tumours, and may help explain their increased immunogenicity and excellent prognosis.   
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Figure legends 
 
Figure 1. Pathogenic, somatic POLE exonuclease domain mutations in precursors of 
endometrial and colorectal cancers 
Expert histopathological review of 51 endometrial cancers with pathogenic POLE 
exonuclease domain mutations revealed four with concomitant and spatially discrete area of 
endometrial intraepithelial neoplasia (EIN). (A) H&E stained section from one case with 
results of Sanger sequencing of the malignant and precursor components. (B) Targeted 
sequencing of paired endometrial lesions by two orthogonal next generation sequencing 
panels revealed that POLE mutations (bold, underlined) were present in both EIN and 
carcinomas in all cases (validated by Sanger sequencing in all cases). In each case, 
progression of EIN to endometrial carcinoma was associated with the gain of driver 
mutations, several of which were glutamic acid or arginine to stop codon mutations (E→* or 
R→ *) consistent with the POLE exonuclease domain-mutant mutational signature 
(semibold). †The amount of DNA available from the EIN in case Q1-4 was insufficient for 
molecular inversion probe sequencing. Details of identified driver mutations are provided in 
supplementary material, Table S7. (C) H&E stained section from colorectal adenoma with the 
results of Sanger sequencing and allelic discrimination PCR for the wild-type G allele and 
mutant T allele. 
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Figure 2. Whole genome sequencing of cancers with POLE exonuclease domain 
mutations 
(A) Mutation burden and single nucleotide variant (SNV) type determined by whole genome 
sequencing (WGS) of five endometrial cancers (EC– Oxf001, POLE_040, POLE_049, POLE 
072, POLE_147) and one colorectal cancer (CRC – Bir001) with somatic POLEP286R 
exonuclease domain mutations. (B) Relative proportion of SNV mutations according to 
trinucleotide context averaged across the six POLE-mutant cases. The upper panel shows the 
unscaled proportions across the whole genome, while the lower panel shows the inferred 
mutational signature in a hypothetical genome where all trinucleotide frequencies are 
represented in equal proportions. High resolution versions are provided in supplementary 
material, Figure S1 (C) Frequency histograms and kernel density plots showing variant allele 
fraction (VAF) of all SNV mutations, and SNVs likely due to POLE exonuclease domain 
mutation (POLE). POLE mutations and other driver gene mutations are highlighted by 
arrows (details provided in supplementary material, Table S8). Only mutations in diploid 
regions of autosomes, and with coverage >20x are shown. The relatively low proportion of 
SNVs categorised as being due to POLE mutation reflects the stringency of the classification 
used (see Materials and methods, Mutational signatures). Vertical red line indicates clonal 
peak used to calculate cellularity.  
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Figure 3. POLE signature mutations in endometrial cancer driver genes  
Heatmap showing modelled probability that mutations in endometrial cancer driver genes 
(defined based on IntOGen – see Materials and methods, Definition of driver genes; 
supplementary material, Table S5) were due to a prior POLE exonuclease domain mutation. 
Results are shown for samples with a pathogenic POLE mutation and MMR-D and MMR-P 
comparators. Each non-synonymous mutation in a driver gene was assigned a probability that 
it was caused by the mutational process that generates the distinct POLE mutational 
signature, rather than by the mutational processes responsible for the consensus mutational 
signatures of POLE-wild-type DNA mismatch repair proficient (MMR-P) and mismatch 
repair deficient (MMR-D) tumours (see Materials and methods, POLE consensus mutational 
signature scores in driver genes, for details. For each gene/sample combination, a ‘POLE-
score’ was then calculated as the minimum value of these ratios, and plotted as a heatmap. 
Scores are shown for both individual POLE-mutant tumours and the combined POLE-mutant 
subgroup; results for tumours within the POLE-wild-type, mismatch repair proficient (MMR-
P) and POLE-wild-type, mismatch repair deficient (MMR-D) subgroups are combined for 
clarity. Scores for POLE itself are shown for reference. Details of mutations are provided in 
supplementary material, Tables S8, S9. A high resolution version of this figure is provided as 
supplementary material, Figure S4.  
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Figure 4. POLE signature mutations in colorectal cancer driver genes  
Corresponding heatmap to Figure 3 showing results for known colorectal cancer driver genes, 
(defined base on IntOGen – see Materials and methods, Definition of driver genes; 
supplementary material, Table S4). Details of mutations are provided in supplementary 
material, Tables S8, S10. A high resolution version of this figure is provided as 
supplementary material, Figure S5. 
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Figure 5. T cell infiltrate in POLE-mutant precursor lesions 
(A) Representative images of immunohistochemistry (IHC) for the cytotoxic T cell marker 
CD8 in endometrial intraepithelial neoplasias (EIN) and paired concomitant endometrioid 
adenocarcinomas and in colorectal adenomas according to POLE mutation status. (B) 
Quantification of CD8+ infiltrate density (number of CD8+ cells per high power field [HPF] 
calculated as the mean of 10 high power fields) in POLE-wild-type and POLE-mutant paired 
endometrial intraepithelial neoplasia (EIN) and endometrial carcinoma (EC) (n=4 EIN–
carcinoma pairs for each genotype) and in POLE-wild-type and POLE-mutant colorectal 
adenomas (Ad) (n=5 POLE-wild-type lesions, and the single POLE-mutant adenoma 
informative for analysis). Symbols (square, circle, triangle and diamond) correspond to paired 
EIN and endometrial carcinomas for POLE-wild-type (open symbols) and POLE-mutant 
(closed symbols) cases. For colorectal adenomas open and closed triangles correspond to 
unpaired POLE-wild-type and POLE-mutant adenomas respectively.  Statistical comparisons 
in (B) were performed by unadjusted Mann-Whitney U-test. HPF – high power field.  
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Figure S1. Relative proportion of SNV mutations according to trinucleotide context in six 
POLE-mutant tumour genomes (high resolution image) 
Figure S2. Clonality of POLE mutations and mutational processes in TCGA endometrial 
cancers 
Figure S3. Clonality of POLE mutations and mutational processes in TCGA colorectal 
cancers 
Figure S4. POLE signature mutations in endometrial cancer driver genes (high resolution 
image). 
Figure S5 POLE signature mutations in colorectal cancer driver genes (high resolution 
image). 
Figure S6. POLE signature in high-confidence endometrial cancer driver mutations 
Figure S7. POLE signature in high-confidence colorectal cancer driver mutations 
Figure S8. Driver mutations in TCGA endometrial cancers 
Figure S9. Driver mutations in  TCGA colorectal cancers 
Figure S10. Driver mutations in LUMC endometrial cancers 
Figure S11. Clonality of neoantigens in TCGA colorectal cancers 
Table S1. Cohorts analysed and molecular analyses performed 
Table S2. Details of cases used for molecular analyses 
Table S3. Genes included in custom molecular inversion probe panel 
Table S4. Genes included in custom Ion AmpliSeq Cancer Hotspot Panel 
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Table S6. List of IntOGen colorectal cancer driver genes used in this study 
Table S7. Driver mutations detected in paired endometrial intraepithelial neoplasias (EIN) 
and endometrial carcinomas 
Table S8. Driver mutations in POLE-mutant cancers analysed by whole genome sequencing 
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